Logo
x

Search

Subscribe Now

P-ll

AstraZeneca to Unveil its Robust Pipeline of Breast Cancer at SABCS

AstraZeneca to Unveil its Robust Pipeline of Breast Cancer at SABCS

  • December 3, 2020
BioNTech and Fosun Pharma Initiate P-ll Study of BNT162b2 Against COVID-19 in China

BioNTech and Fosun Pharma Initiate P-ll Study of BNT162b2 Against COVID-19 in China

  • November 26, 2020
Regeneron Pauses Dosing of Garetosmab (REGN2477) in P-II LUMINA-1 Study for Fibrodysplasia Ossificans Progressiva

Regeneron Pauses Dosing of Garetosmab (REGN2477) in P-II LUMINA-1 Study for Fibrodysplasia Ossificans Progressiva

  • November 2, 2020
Lilly Reports Results of Mirikizumab in P-ll SERENITY Study for Crohn's Disease

Lilly Reports Results of Mirikizumab in P-ll SERENITY Study for Crohn's Disease

  • October 13, 2020
Amgen Report Five Year Data of Aimovig (erenumab-aooe) in Open-Label Treatment Period of P-II Study for Episodic Migraine

Amgen Report Five Year Data of Aimovig (erenumab-aooe) in Open-Label Treatment Period of P-II Study for Episodic Migraine

  • October 5, 2020
CureVac Commences P-llb/lll Trial of CVnCoV for COVID-19

    CureVac Commences P-llb/lll Trial of CVnCoV for COVID-19

    • December 15, 2020
    Novartis

      Novartis' Ruxolitinib Fails to Meet its Primary Endpoint in P-lll RUXCOVID Study for COVID-19

      • December 14, 2020
      Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes

        Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes

        • December 10, 2020
        Novartis

          Novartis' Asciminib (ABL001) Demonstrate Superiority Over Pfizer's Bosulif in Chronic Myeloid Leukemia Trial

          • December 9, 2020
          AstraZeneca Reports Results of AZD1222 in Interim Analysis of P-lll Program for COVID-19

            AstraZeneca Reports Results of AZD1222 in Interim Analysis of P-lll Program for COVID-19

            • December 9, 2020
            AbbVie Reports Results of Imbruvica (ibrutinib) in Two P-III Studies as 1L Treatment for Chronic Lymphocytic Leukemia

              AbbVie Reports Results of Imbruvica (ibrutinib) in Two P-III Studies as 1L Treatment for Chronic Lymphocytic Leukemia

              • December 8, 2020
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.